Alexion Pharmaceuticals, Inc. (ALXN)

[mlkrborn]

Alexion Pharma: Longer-term data on Soliris showed significant and sustained benefits for patients with aHUS (ALXN) 63.94 -0.13 : Co presented longer-term data from the extensions of two pivotal phase 2 studies of Soliris in patients with atypical hemolytic uremic syndrome: (i) a study in patients with a long duration of disease prior to receiving intervention with Soliris following chronic plasma exchange/infusion and (ii) a study in patients with a shorter duration of disease prior to intervention with Soliris who had progressive clinical complications despite intensive PE/PI. Results demonstrated that ongoing treatment with Soliris sustained the suppression of complement-mediated thrombotic microangiopathy, maintained or further improved longer-term renal function, and enhanced quality of life. The primary endpoint of TMA event-free status was achieved by 16 of 20 Soliris-treated patients (80%) by week 26 and was sustained through the extension study, indicating that chronic treatment with Soliris continued to significantly inhibit complement-mediated TMA and progression of kidney dysfunction.